Financhill
Sell
34

MGNX Quote, Financials, Valuation and Earnings

Last price:
$1.55
Seasonality move :
-11.43%
Day range:
$1.47 - $1.58
52-week range:
$0.99 - $5.77
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.63x
P/B ratio:
1.21x
Volume:
796K
Avg. volume:
2M
1-year change:
-71.77%
Market cap:
$95.9M
Revenue:
$148.3M
EPS (TTM):
-$0.89

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
MGNX
Macrogenics
$28.1M $0.38 159.87% -25.84% $4.20
CLRB
Cellectar Biosciences
-- -$3.70 -- -31.48% $4.00
DARE
Dare Bioscience
$141.5K -$0.58 -100% -28.4% $13.00
MBRX
Moleculin Biotech
-- -- -- -- $7.00
PODD
Insulet
$612.3M $0.92 25.31% -64.13% $336.85
ZVRA
Zevra Therapeutics
$22.5M $1.61 405.53% -54.64% $22.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
MGNX
Macrogenics
$1.52 $4.20 $95.9M -- $0.00 0% 0.63x
CLRB
Cellectar Biosciences
$5.04 $4.00 $9.1M -- $0.00 0% 137.94x
DARE
Dare Bioscience
$2.62 $13.00 $23.2M -- $0.00 0% 854.30x
MBRX
Moleculin Biotech
$0.64 $7.00 $9M -- $0.00 0% --
PODD
Insulet
$288.27 $336.85 $20.3B 51.85x $0.00 0% 9.70x
ZVRA
Zevra Therapeutics
$12.32 $22.75 $673.7M -- $0.00 0% 14.97x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
MGNX
Macrogenics
-- 0.939 -- 2.97x
CLRB
Cellectar Biosciences
-- 0.590 -- --
DARE
Dare Bioscience
-- -0.919 -- 0.49x
MBRX
Moleculin Biotech
-- 0.045 -- --
PODD
Insulet
56.03% 1.967 9.18% 3.24x
ZVRA
Zevra Therapeutics
59.43% 1.483 14.67% 2.79x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
MGNX
Macrogenics
$7.8M -$42.6M -58.23% -58.23% -310.38% -$47.4M
CLRB
Cellectar Biosciences
-- -$6.4M -- -- -- -$9.4M
DARE
Dare Bioscience
$25.4K -$4.6M -- -- -18016.75% -$5.6M
MBRX
Moleculin Biotech
-- -$5.9M -- -- -- -$4.6M
PODD
Insulet
$409M $88.8M 15.79% 36.9% 10.07% $48.1M
ZVRA
Zevra Therapeutics
$19.1M -$5.4M -89.91% -198.46% 0.26% -$8.3M

Macrogenics vs. Competitors

  • Which has Higher Returns MGNX or CLRB?

    Cellectar Biosciences has a net margin of -311.07% compared to Macrogenics's net margin of --. Macrogenics's return on equity of -58.23% beat Cellectar Biosciences's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MGNX
    Macrogenics
    59.07% -$0.65 $79.1M
    CLRB
    Cellectar Biosciences
    -- -$4.20 --
  • What do Analysts Say About MGNX or CLRB?

    Macrogenics has a consensus price target of $4.20, signalling upside risk potential of 176.32%. On the other hand Cellectar Biosciences has an analysts' consensus of $4.00 which suggests that it could grow by 2280.96%. Given that Cellectar Biosciences has higher upside potential than Macrogenics, analysts believe Cellectar Biosciences is more attractive than Macrogenics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MGNX
    Macrogenics
    1 5 0
    CLRB
    Cellectar Biosciences
    2 2 0
  • Is MGNX or CLRB More Risky?

    Macrogenics has a beta of 1.587, which suggesting that the stock is 58.67% more volatile than S&P 500. In comparison Cellectar Biosciences has a beta of 0.507, suggesting its less volatile than the S&P 500 by 49.315%.

  • Which is a Better Dividend Stock MGNX or CLRB?

    Macrogenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectar Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Macrogenics pays -- of its earnings as a dividend. Cellectar Biosciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MGNX or CLRB?

    Macrogenics quarterly revenues are $13.2M, which are larger than Cellectar Biosciences quarterly revenues of --. Macrogenics's net income of -$41M is lower than Cellectar Biosciences's net income of -$6.6M. Notably, Macrogenics's price-to-earnings ratio is -- while Cellectar Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Macrogenics is 0.63x versus 137.94x for Cellectar Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MGNX
    Macrogenics
    0.63x -- $13.2M -$41M
    CLRB
    Cellectar Biosciences
    137.94x -- -- -$6.6M
  • Which has Higher Returns MGNX or DARE?

    Dare Bioscience has a net margin of -311.07% compared to Macrogenics's net margin of -17219.13%. Macrogenics's return on equity of -58.23% beat Dare Bioscience's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MGNX
    Macrogenics
    59.07% -$0.65 $79.1M
    DARE
    Dare Bioscience
    17.5% -$0.50 -$9.6M
  • What do Analysts Say About MGNX or DARE?

    Macrogenics has a consensus price target of $4.20, signalling upside risk potential of 176.32%. On the other hand Dare Bioscience has an analysts' consensus of $13.00 which suggests that it could grow by 396.18%. Given that Dare Bioscience has higher upside potential than Macrogenics, analysts believe Dare Bioscience is more attractive than Macrogenics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MGNX
    Macrogenics
    1 5 0
    DARE
    Dare Bioscience
    2 1 0
  • Is MGNX or DARE More Risky?

    Macrogenics has a beta of 1.587, which suggesting that the stock is 58.67% more volatile than S&P 500. In comparison Dare Bioscience has a beta of 1.138, suggesting its more volatile than the S&P 500 by 13.754%.

  • Which is a Better Dividend Stock MGNX or DARE?

    Macrogenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dare Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Macrogenics pays -- of its earnings as a dividend. Dare Bioscience pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MGNX or DARE?

    Macrogenics quarterly revenues are $13.2M, which are larger than Dare Bioscience quarterly revenues of $25.4K. Macrogenics's net income of -$41M is lower than Dare Bioscience's net income of -$4.4M. Notably, Macrogenics's price-to-earnings ratio is -- while Dare Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Macrogenics is 0.63x versus 854.30x for Dare Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MGNX
    Macrogenics
    0.63x -- $13.2M -$41M
    DARE
    Dare Bioscience
    854.30x -- $25.4K -$4.4M
  • Which has Higher Returns MGNX or MBRX?

    Moleculin Biotech has a net margin of -311.07% compared to Macrogenics's net margin of --. Macrogenics's return on equity of -58.23% beat Moleculin Biotech's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MGNX
    Macrogenics
    59.07% -$0.65 $79.1M
    MBRX
    Moleculin Biotech
    -- -$0.69 --
  • What do Analysts Say About MGNX or MBRX?

    Macrogenics has a consensus price target of $4.20, signalling upside risk potential of 176.32%. On the other hand Moleculin Biotech has an analysts' consensus of $7.00 which suggests that it could grow by 993.75%. Given that Moleculin Biotech has higher upside potential than Macrogenics, analysts believe Moleculin Biotech is more attractive than Macrogenics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MGNX
    Macrogenics
    1 5 0
    MBRX
    Moleculin Biotech
    1 0 0
  • Is MGNX or MBRX More Risky?

    Macrogenics has a beta of 1.587, which suggesting that the stock is 58.67% more volatile than S&P 500. In comparison Moleculin Biotech has a beta of 1.381, suggesting its more volatile than the S&P 500 by 38.119%.

  • Which is a Better Dividend Stock MGNX or MBRX?

    Macrogenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moleculin Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Macrogenics pays -- of its earnings as a dividend. Moleculin Biotech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MGNX or MBRX?

    Macrogenics quarterly revenues are $13.2M, which are larger than Moleculin Biotech quarterly revenues of --. Macrogenics's net income of -$41M is lower than Moleculin Biotech's net income of -$6.4M. Notably, Macrogenics's price-to-earnings ratio is -- while Moleculin Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Macrogenics is 0.63x versus -- for Moleculin Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MGNX
    Macrogenics
    0.63x -- $13.2M -$41M
    MBRX
    Moleculin Biotech
    -- -- -- -$6.4M
  • Which has Higher Returns MGNX or PODD?

    Insulet has a net margin of -311.07% compared to Macrogenics's net margin of 6.22%. Macrogenics's return on equity of -58.23% beat Insulet's return on equity of 36.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    MGNX
    Macrogenics
    59.07% -$0.65 $79.1M
    PODD
    Insulet
    71.88% $0.50 $3B
  • What do Analysts Say About MGNX or PODD?

    Macrogenics has a consensus price target of $4.20, signalling upside risk potential of 176.32%. On the other hand Insulet has an analysts' consensus of $336.85 which suggests that it could grow by 16.85%. Given that Macrogenics has higher upside potential than Insulet, analysts believe Macrogenics is more attractive than Insulet.

    Company Buy Ratings Hold Ratings Sell Ratings
    MGNX
    Macrogenics
    1 5 0
    PODD
    Insulet
    15 3 0
  • Is MGNX or PODD More Risky?

    Macrogenics has a beta of 1.587, which suggesting that the stock is 58.67% more volatile than S&P 500. In comparison Insulet has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.619%.

  • Which is a Better Dividend Stock MGNX or PODD?

    Macrogenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Macrogenics pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MGNX or PODD?

    Macrogenics quarterly revenues are $13.2M, which are smaller than Insulet quarterly revenues of $569M. Macrogenics's net income of -$41M is lower than Insulet's net income of $35.4M. Notably, Macrogenics's price-to-earnings ratio is -- while Insulet's PE ratio is 51.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Macrogenics is 0.63x versus 9.70x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MGNX
    Macrogenics
    0.63x -- $13.2M -$41M
    PODD
    Insulet
    9.70x 51.85x $569M $35.4M
  • Which has Higher Returns MGNX or ZVRA?

    Zevra Therapeutics has a net margin of -311.07% compared to Macrogenics's net margin of -15.19%. Macrogenics's return on equity of -58.23% beat Zevra Therapeutics's return on equity of -198.46%.

    Company Gross Margin Earnings Per Share Invested Capital
    MGNX
    Macrogenics
    59.07% -$0.65 $79.1M
    ZVRA
    Zevra Therapeutics
    93.41% -$0.06 $101.1M
  • What do Analysts Say About MGNX or ZVRA?

    Macrogenics has a consensus price target of $4.20, signalling upside risk potential of 176.32%. On the other hand Zevra Therapeutics has an analysts' consensus of $22.75 which suggests that it could grow by 84.66%. Given that Macrogenics has higher upside potential than Zevra Therapeutics, analysts believe Macrogenics is more attractive than Zevra Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MGNX
    Macrogenics
    1 5 0
    ZVRA
    Zevra Therapeutics
    4 0 0
  • Is MGNX or ZVRA More Risky?

    Macrogenics has a beta of 1.587, which suggesting that the stock is 58.67% more volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 1.965, suggesting its more volatile than the S&P 500 by 96.525%.

  • Which is a Better Dividend Stock MGNX or ZVRA?

    Macrogenics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Macrogenics pays -- of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MGNX or ZVRA?

    Macrogenics quarterly revenues are $13.2M, which are smaller than Zevra Therapeutics quarterly revenues of $20.4M. Macrogenics's net income of -$41M is lower than Zevra Therapeutics's net income of -$3.1M. Notably, Macrogenics's price-to-earnings ratio is -- while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Macrogenics is 0.63x versus 14.97x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MGNX
    Macrogenics
    0.63x -- $13.2M -$41M
    ZVRA
    Zevra Therapeutics
    14.97x -- $20.4M -$3.1M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will GoodRX Stock Bounce Back?
Will GoodRX Stock Bounce Back?

GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…

Will FCX Benefit From Tariffs?
Will FCX Benefit From Tariffs?

Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…

Can Levi Stock Double?
Can Levi Stock Double?

Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…

Stock Ideas

Buy
70
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 58x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
82
SBET alert for Jul 17

SharpLink Gaming [SBET] is down 2.6% over the past day.

Buy
89
EXOD alert for Jul 17

Exodus Movement [EXOD] is down 4.14% over the past day.

Buy
60
U alert for Jul 17

Unity Software [U] is up 7.51% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock